“Real-World Evidence Confirms Risk Stratification of the 31-GEP and i31-GEP in Prospectively Tested Patients With Stage I-III Cutaneous Melanoma ”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 2, Mar. 2024, p. s386, https://doi.org/10.25251/skin.8.supp.386.